Clinical utility of ABCB1 single nucleotide polymorphism on tacrolimus dose requirements in Egyptian liver transplant patients

Egyptian Liver Journal

Table 4 Relation of ABCB1 genotype and C/D ratio, tacrolimus dose, and trough levels among the recipient group 2 months and 3 months post transplantation (Mann–Whitney test)

ABCB1		CC	CT+TT	Z	P-value	Sig.
2nd month
Dose	Median (IQR)	0.1 (0.07–0.1)	0.05(0.03–0.08)	−1.902	0.050	S
Dose	Range	0.04–0.1	0.02–0.1	−1.902	0.050	S
Trough level	Median (IQR)	5.3(3.8–10.6)	6.65(6.05–7.8)	−0.797	0.426	NS
Trough level	Range	2.9–12.9	2.2–14.6	−0.797	0.426	NS
C/D	Median (IQR)	63.5(49–106)	126.5(88.25–207.5)	−2.154	0.031	S
C/D	Range	47–143	55–486	−2.154	0.031	S
3rd month
Dose	Median (IQR)	0.08(0.05–0.09)	0.05(0.03–0.07)	−1.508	0.132	NS
Dose	Range	0.02–0.1	0.01–0.1	−1.508	0.132	NS
Trough level	Median (IQR)	4.95(4.5–7.4)	5.8(3.3–7)	−0.188	0.851	NS
Trough level	Range	3.2–8.8	1.4–9.1	−0.188	0.851	NS
C/D	Median (IQR)	76.5(61–176)	122(84.5–147.5)	−0.469	0.639	NS
C/D	Range	32–225	47–205	−0.469	0.639	NS

P-value >0.05, non-significant (NS); P-value <0.05, significant (S); P-value< 0.01, highly significant (HS)